Cite
APA Citation
Cohen, J. A., Cameron, M. H., Goldman, M. D., Goodman, A. D., Miller, A. E., Rollins, A., Llorens, L., Patni, R., Elfont, R., & Johnson, R. (2022). a Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple sclerosis, 28, 817–830. http://access.bl.uk/ark:/81055/vdc_100147158190.0x00001b